BIP Asia 2017

2017年12月7日

Our recently created Chau Eagle Global IP had a successful exhibition at the BIP Asia 2017.

Chau Eagle Global IP is a merged practice between two top tier IP boutiques, Eagle IP in HK and F. Chau & Associates in New York. F. Chau & Associates, has been ranked No. 1 in New York (and No. 6 in the United States) for patent quality in consumer electronics by Ocean Tomo.

我们的过去活动

Insights from HKSTP Market Discovery - BIO Connect

2025年5月28日

HKMHDIA Medical Fair Forum

2025年5月27日

Celebrating Innovation at the Asia Summit for Global Health

2025年5月26日

Eagle IP Celebrates 20th Anniversary, Reflecting on Two Decades of Excellence

2025年5月21日

Eagle IP is Coming Back to LSPN in Boston!

2025年4月24日

AIPLA Women in IP Global Networking Event in Hong Kong

2025年4月3日

Recommended Insights

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日

Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]

A Detailed Dive into China’s New Patent Term Extension Provisions

2020年12月11日

This article is a part of a larger article that highlights the newest draft implementation rules of the new Chinese Patent Law. This particular article takes a detailed dive into the patent term extension/adjustment provisions. One of the biggest and most exciting provisions in the newly amended patent law is patent term extension for delay […]

Chinese Courts Cares More About Patent Quality Now (A Doctrine of Equivalents Story)

2022年12月13日

There is no doubt that the drafting quality of a patent can be crucial in determining the success (or failure!) of the patent during litigation. However, due to various reasons, patents often fail to use the right drafting strategies that best protect the invention. Too often, inexperienced or unsophisticated patent drafters merely listen to an […]

RNAi Patent Success in China: Overcoming “Comprising” Claim Challenges

2025年3月10日

An Update on Sufficiency and Inventiveness of RNAi Patents in China RNAi is a fast-developing technology that has gained traction in the pharmaceutical industry as a promising therapeutic agent. It is important to follow closely RNAi patent proceedings to learn how different examination boards and courts understand and handle these new technologies. The first-ever invalidation […]